Scisparc Ltd (SPRC)

$5.43 -0.63 (-10.40%)
Market Cap 3.43M
Revenue (ttm) 860,000.00
Net Income (ttm) -12.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,416.28%
Debt to Equity Ratio 0.07
Volume 15,600
Avg Vol 507,831
Day's Range N/A - N/A
Shares Out 566,000.00
Stochastic %K 3%
Beta 2.71
Analysts Strong Buy
Price Target $20.00

Company Profile

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially man...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 7 334 47180
Address:
Tower A, 2nd Floor 20 Raul Wallenberg Street, Tel Aviv-Yafo, Israel
JNbee
JNbee May. 12 at 11:14 PM
$SPRC what the f? lol going down for forever!
0 · Reply
JNbee
JNbee May. 11 at 5:13 PM
$SPRC Jews
0 · Reply
JNbee
JNbee May. 8 at 9:13 PM
$SPRC Delist this Jewish soon enough!
0 · Reply
ciggycapital
ciggycapital May. 7 at 3:59 PM
$SMX $SPRC everyone please block this guy hahahahahaha
1 · Reply
MovingFast77
MovingFast77 May. 7 at 1:00 AM
$SPRC Time to turn around
1 · Reply
JNbee
JNbee May. 6 at 10:07 PM
$SPRC never seen a stock going down 5 days in a row of more than 30% in green days..
0 · Reply
JNbee
JNbee May. 5 at 12:02 PM
$SPRC Israeli scams should be removed from Nasdaq... seriously..
0 · Reply
JNbee
JNbee May. 4 at 12:18 PM
$SPRC Jewish scam...
0 · Reply
MovingFast77
MovingFast77 Apr. 30 at 3:54 PM
$GPRO $SMX $SPRC all ready for lift off All ready for #shortsqueeze
0 · Reply
JNbee
JNbee Apr. 30 at 1:32 PM
$SPRC lol
0 · Reply
Latest News on SPRC
Neurothera Labs Announces Continuance into Ontario

Apr 30, 2026, 8:00 AM EDT - 13 days ago

Neurothera Labs Announces Continuance into Ontario

Neurothera Labs Engages bullVestor for Investor Relations Activities

Apr 23, 2026, 6:00 PM EDT - 19 days ago

Neurothera Labs Engages bullVestor for Investor Relations Activities

SciSparc discloses patent application for depression yherapy

2026-03-16T12:25:23.000Z - 2 months ago

SciSparc discloses patent application for depression yherapy

SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

Mar 16, 2026, 8:20 AM EDT - 2 months ago

SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

SciSparc’s Neurothera Labs announces publication of international patent

2026-03-12T12:01:25.000Z - 2 months ago

SciSparc’s Neurothera Labs announces publication of international patent

CMND

SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Mar 12, 2026, 7:55 AM EDT - 2 months ago

SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

SciSparc says Neurothera Labs agrees to acquire majority stake in CliniQuantum

2026-03-10T13:38:10.000Z - 2 months ago

SciSparc says Neurothera Labs agrees to acquire majority stake in CliniQuantum

SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails

Mar 10, 2026, 9:28 AM EDT - 2 months ago

SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails

Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Mar 10, 2026, 8:59 AM EDT - 2 months ago

Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

CMND

Neurothera Labs Inc. Announces Definitive Agreement To Acquire Majority Stake In Cliniquantum Ltd.

Mar 10, 2026, 7:30 AM EDT - 2 months ago

Neurothera Labs Inc. Announces Definitive Agreement To Acquire Majority Stake In Cliniquantum Ltd.

Scisparc Ltd trading halted, news pending

2026-03-04T00:50:09.000Z - 2 months ago

Scisparc Ltd trading halted, news pending

SciSparc announces 1-for-9 reverse share split

2026-03-02T13:35:06.000Z - 2 months ago

SciSparc announces 1-for-9 reverse share split

SciSparc announces 1-for-9 reverse share split

2026-03-02T13:28:37.000Z - 2 months ago

SciSparc announces 1-for-9 reverse share split

SciSparc announces 1-for-9 reverse share split

2026-03-02T13:23:28.000Z - 2 months ago

SciSparc announces 1-for-9 reverse share split

SciSparc Announces 1-for-9 Reverse Share Split

Mar 2, 2026, 8:00 AM EST - 2 months ago

SciSparc Announces 1-for-9 Reverse Share Split

SciSparc files to sell 23.04M ordinary shares for holders

2026-02-17T22:30:16.000Z - 3 months ago

SciSparc files to sell 23.04M ordinary shares for holders

SciSparc files $50M mixed securities shelf

2026-02-03T21:40:29.000Z - 3 months ago

SciSparc files $50M mixed securities shelf

SciSparc says Neurothera Labs granted U.S. patent for cannabinoid tech

2026-02-02T13:36:11.000Z - 3 months ago

SciSparc says Neurothera Labs granted U.S. patent for cannabinoid tech

SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA

Feb 2, 2026, 8:24 AM EST - 3 months ago

SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA

Neurothera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA

Feb 2, 2026, 8:00 AM EST - 3 months ago

Neurothera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA

SciSparc completes acquisition of IP portfolio of patents, trademarks

2026-01-26T13:20:59.000Z - 3 months ago

SciSparc completes acquisition of IP portfolio of patents, trademarks

SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization

Jan 26, 2026, 8:13 AM EST - 3 months ago

SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization

SciSparc to acquire a treasury of patents for the endoscope market

2026-01-13T12:00:18.000Z - 4 months ago

SciSparc to acquire a treasury of patents for the endoscope market

SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity

Jan 13, 2026, 6:55 AM EST - 4 months ago

SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity

SciSparc receives noncompliance notification from Nasdaq

2026-01-12T21:11:27.000Z - 4 months ago

SciSparc receives noncompliance notification from Nasdaq

SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

Jan 12, 2026, 4:02 PM EST - 4 months ago

SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

Neurothera Labs Announces Results of AGM

Jan 8, 2026, 6:00 PM EST - 4 months ago

Neurothera Labs Announces Results of AGM

SciSparc says Neurothera Labs granted patent by Israeli Patent Office

2025-12-30T13:35:26.000Z - 4 months ago

SciSparc says Neurothera Labs granted patent by Israeli Patent Office

SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects

Dec 30, 2025, 8:17 AM EST - 4 months ago

SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects

Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects

Dec 30, 2025, 8:00 AM EST - 4 months ago

Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects

NeuroThera to acquire 55% stake in quantum computing bio data company

2025-12-02T14:35:56.000Z - 5 months ago

NeuroThera to acquire 55% stake in quantum computing bio data company

SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company

Dec 2, 2025, 9:29 AM EST - 5 months ago

SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company

Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company

Dec 2, 2025, 8:05 AM EST - 5 months ago

Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company

SciSparc plans to enter GERD device market with IP portfolio acquisition

2025-12-01T13:45:49.000Z - 5 months ago

SciSparc plans to enter GERD device market with IP portfolio acquisition

SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP Portfolio

Dec 1, 2025, 8:32 AM EST - 5 months ago

SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP Portfolio

SciSparc to acquire treasury of patents for medical endoscopy systems

2025-11-26T12:51:05.000Z - 5 months ago

SciSparc to acquire treasury of patents for medical endoscopy systems

SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems

Nov 26, 2025, 7:38 AM EST - 5 months ago

SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems

SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Nov 20, 2025, 6:42 AM EST - 6 months ago

SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Nov 19, 2025, 8:30 AM EST - 6 months ago

Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

CMND

SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio

Oct 24, 2025, 7:55 AM EDT - 7 months ago

SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio

SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

Oct 23, 2025, 4:03 PM EDT - 7 months ago

SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery

Oct 23, 2025, 8:55 AM EDT - 7 months ago

SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery

Scisparc Ltd. - Early Warning Regarding Acquisition Of Common Shares Of Neurothera Labs Inc.

Oct 22, 2025, 3:30 PM EDT - 7 months ago

Scisparc Ltd. - Early Warning Regarding Acquisition Of Common Shares Of Neurothera Labs Inc.

SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders

Oct 20, 2025, 7:41 AM EDT - 7 months ago

SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders

SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio

Oct 15, 2025, 7:05 AM EDT - 7 months ago

SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio

SciSparc Ltd. Announces Framework Agreement Regarding Merger with AutoMax Motors

Oct 6, 2025, 6:40 AM EDT - 7 months ago

SciSparc Ltd. Announces Framework Agreement Regarding Merger with AutoMax Motors

SciSparc: N2OFF Shareholders Approve Merger with SciSparc's Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

Sep 29, 2025, 4:03 PM EDT - 8 months ago

SciSparc: N2OFF Shareholders Approve Merger with SciSparc's Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

SciSparc Resolves to Launch Innovative Quantum Computing-Enabled 3D Protein Modeling Initiative to Revolutionize AI Drug Discovery

Sep 25, 2025, 7:05 AM EDT - 8 months ago

SciSparc Resolves to Launch Innovative Quantum Computing-Enabled 3D Protein Modeling Initiative to Revolutionize AI Drug Discovery

SciSparc: AutoMax's Shareholders Approve Merger with SciSparc

Aug 28, 2025, 9:24 AM EDT - 9 months ago

SciSparc: AutoMax's Shareholders Approve Merger with SciSparc

SciSparc Shareholders Approve Merger with a Leading Parallel Vehicle Importer in Israel

Aug 28, 2025, 6:45 AM EDT - 9 months ago

SciSparc Shareholders Approve Merger with a Leading Parallel Vehicle Importer in Israel

SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

Aug 7, 2025, 7:32 AM EDT - 9 months ago

SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC

Jul 30, 2025, 4:34 PM EDT - 10 months ago

SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease

Jul 30, 2025, 8:12 AM EDT - 10 months ago

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease

SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification

Jul 22, 2025, 7:32 AM EDT - 10 months ago

SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification

SciSparc Announces 1-for-21 Reverse Share Split

Jun 24, 2025, 5:03 PM EDT - 11 months ago

SciSparc Announces 1-for-21 Reverse Share Split

SciSparc Announces Publication of Japanese Patent Application

May 27, 2025, 7:32 AM EDT - 1 year ago

SciSparc Announces Publication of Japanese Patent Application

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

Apr 25, 2025, 7:59 AM EDT - 1 year ago

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

CMND

SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers

Mar 3, 2025, 8:25 AM EST - 1 year ago

SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers

SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into Direct Import of JAC Electric Vehicles

Feb 27, 2025, 8:45 AM EST - 1 year ago

SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into Direct Import of JAC Electric Vehicles

SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology

Feb 18, 2025, 7:17 AM EST - 1 year ago

SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology

SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

Feb 4, 2025, 9:00 AM EST - 1 year ago

SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

Jan 15, 2025, 7:34 AM EST - 1 year ago

SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles

Jan 13, 2025, 8:41 AM EST - 1 year ago

SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles

SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results

Jan 7, 2025, 7:25 AM EST - 1 year ago

SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results

SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

Jan 6, 2025, 7:50 AM EST - 1 year ago

SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder

Dec 31, 2024, 9:24 AM EST - 1 year ago

SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

Dec 26, 2024, 6:46 AM EST - 1 year ago

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

JNbee
JNbee May. 12 at 11:14 PM
$SPRC what the f? lol going down for forever!
0 · Reply
JNbee
JNbee May. 11 at 5:13 PM
$SPRC Jews
0 · Reply
JNbee
JNbee May. 8 at 9:13 PM
$SPRC Delist this Jewish soon enough!
0 · Reply
ciggycapital
ciggycapital May. 7 at 3:59 PM
$SMX $SPRC everyone please block this guy hahahahahaha
1 · Reply
MovingFast77
MovingFast77 May. 7 at 1:00 AM
$SPRC Time to turn around
1 · Reply
JNbee
JNbee May. 6 at 10:07 PM
$SPRC never seen a stock going down 5 days in a row of more than 30% in green days..
0 · Reply
JNbee
JNbee May. 5 at 12:02 PM
$SPRC Israeli scams should be removed from Nasdaq... seriously..
0 · Reply
JNbee
JNbee May. 4 at 12:18 PM
$SPRC Jewish scam...
0 · Reply
MovingFast77
MovingFast77 Apr. 30 at 3:54 PM
$GPRO $SMX $SPRC all ready for lift off All ready for #shortsqueeze
0 · Reply
JNbee
JNbee Apr. 30 at 1:32 PM
$SPRC lol
0 · Reply
JustBlazed
JustBlazed Apr. 30 at 3:17 AM
$SPRC micro float… wants to run.
0 · Reply
this2shallpass
this2shallpass Apr. 29 at 3:41 PM
$SPRC A Bullish Pennant possibly forming this week on the daily chart
0 · Reply
JNbee
JNbee Apr. 29 at 6:06 AM
$SPRC garbage
0 · Reply
Ozcorp
Ozcorp Apr. 28 at 11:08 AM
$CYCU $JYD $MLEC $PAPL $SPRC
0 · Reply
Love_To_Learn
Love_To_Learn Apr. 28 at 10:10 AM
$SPRC will give u volume later right time stock rotations premarket to intraday etc..........
0 · Reply
Love_To_Learn
Love_To_Learn Apr. 28 at 10:09 AM
$SPRC keep an eye on this ******* back n forth ********
0 · Reply
SadyK189
SadyK189 Apr. 28 at 2:49 AM
Top Stocks to watch tomorrow 2 / 2: $PAPL $SGMT $SPRC $ROLR $CREG PAPL: Initially alerted at 0.94. Currently at 1.32. Looking good on daily chart. Key support at 0.98 - 1.06. Next key level to test 1.65 - 1.78. ROLR: Initially alerted at 7.01. Looking good on daily chart. Key support zone at 9.30 - 9.80. Next key level to test 12.80 - 13.30. Currently at 11.24 CREG: Initially alerted at 0.74. Good close of daily candle. Key support zone at 0.69 - 0.73. Next key level to test 1.07 - 1.18. Currently at 0.9 SPRC: Initially alerted at 6.12. Currently at 8.20. Key support zone at 6.85 - 7.20. Next key level to test 9.30 - 9.65. SGMT: Looking good on 4hours chart. Key support at 7.10 - 7.50. Next key level to test 9.50 - 9.9. Currently at 8.46
0 · Reply
topstockalerts
topstockalerts Apr. 28 at 1:52 AM
Top Gainers PT2 $SEGG $SGMT $CAST $VSA $SPRC
0 · Reply
Love_To_Learn
Love_To_Learn Apr. 28 at 12:27 AM
$SPRC watch the back n forth* *
0 · Reply
InvestingSpaceman
InvestingSpaceman Apr. 27 at 10:05 PM
$SPRC $ONCO run it
0 · Reply
InvestingSpaceman
InvestingSpaceman Apr. 27 at 9:48 PM
$SPRC $ONEG $ELSE $SKLZ ><L>
0 · Reply
MovingFast77
MovingFast77 Apr. 27 at 9:38 PM
$SPRC flying high again as will $SMX with upcoming short squeeze
1 · Reply